IL215831A - A drug containing allopurinol for use in the treatment of hand-foot skin reaction - Google Patents

A drug containing allopurinol for use in the treatment of hand-foot skin reaction

Info

Publication number
IL215831A
IL215831A IL215831A IL21583111A IL215831A IL 215831 A IL215831 A IL 215831A IL 215831 A IL215831 A IL 215831A IL 21583111 A IL21583111 A IL 21583111A IL 215831 A IL215831 A IL 215831A
Authority
IL
Israel
Prior art keywords
allopurinol
medicament
treatment
skin reaction
hand foot
Prior art date
Application number
IL215831A
Other languages
English (en)
Hebrew (he)
Other versions
IL215831A0 (en
Original Assignee
Nobera Pharma Sl
Advancell Advanced In Vitro Cell Tech S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobera Pharma Sl, Advancell Advanced In Vitro Cell Tech S A filed Critical Nobera Pharma Sl
Publication of IL215831A0 publication Critical patent/IL215831A0/en
Publication of IL215831A publication Critical patent/IL215831A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL215831A 2009-04-29 2011-10-23 A drug containing allopurinol for use in the treatment of hand-foot skin reaction IL215831A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (2)

Publication Number Publication Date
IL215831A0 IL215831A0 (en) 2012-01-31
IL215831A true IL215831A (en) 2016-02-29

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215831A IL215831A (en) 2009-04-29 2011-10-23 A drug containing allopurinol for use in the treatment of hand-foot skin reaction

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2488642B1 (en) 2009-10-16 2015-03-11 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
TW201943428A (zh) * 2018-04-16 2019-11-16 大陸商上海岸闊醫藥科技有限公司 預防或治療腫瘤療法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
KR20240159565A (ko) 2022-01-05 2024-11-05 아시메트릭 테라퓨틱스, 엘엘씨 피부 증식성 장애 및 다른 피부 병태 치료를 위한 방법 및 조성물
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2037672T3 (es) * 1987-02-13 1993-07-01 Pharm-Allergan Gmbh Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
BRPI0115531B1 (pt) * 2000-11-22 2015-10-13 Rxkinetix Inc composição terapêutica útil para o tratamento de mucosite em um local de mucosa como efeito colateral de terapia de câncer
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
WO2003018102A2 (en) 2001-08-29 2003-03-06 Vectura Limited Topical administration device
AU2002352982B2 (en) * 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050142093A1 (en) * 2003-12-24 2005-06-30 Gregory Skover Treatment of skin with an apparatus and a benefit agent
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1796660B1 (en) 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
JP5028480B2 (ja) 2006-06-01 2012-09-19 ノベラ ファルマ ソシエダッド リミターダ 手足症候群の治療のためのアロプリノールの使用

Also Published As

Publication number Publication date
WO2010125143A1 (en) 2010-11-04
US20100280051A1 (en) 2010-11-04
CN102421436B (zh) 2014-05-07
RU2011148355A (ru) 2013-06-10
HRP20131070T1 (hr) 2013-12-20
AU2010243594A1 (en) 2011-11-10
US8623878B2 (en) 2014-01-07
BRPI1011971A2 (pt) 2016-04-26
NZ595901A (en) 2013-11-29
CN102421436A (zh) 2012-04-18
US20140080845A1 (en) 2014-03-20
CA2759085C (en) 2016-08-16
CA2759085A1 (en) 2010-11-04
HK1168042A1 (en) 2012-12-21
EP2424538B1 (en) 2013-08-14
ES2434366T3 (es) 2013-12-16
RU2543325C2 (ru) 2015-02-27
SI2424538T1 (sl) 2013-12-31
AU2016228193A1 (en) 2016-11-03
JP6007101B2 (ja) 2016-10-12
MX2011011529A (es) 2012-02-08
IL215831A0 (en) 2012-01-31
DK2424538T3 (da) 2013-11-04
AR076505A1 (es) 2011-06-15
EP2424538A1 (en) 2012-03-07
KR20120049848A (ko) 2012-05-17
JP2012525358A (ja) 2012-10-22
RS53005B (sr) 2014-04-30
PL2424538T3 (pl) 2014-05-30
ME01567B (me) 2014-04-20
PT2424538E (pt) 2013-11-07
EP2246057A1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL213359A0 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
GB2483419B (en) Formulations for the treatment of deep tissue pain
PT2407151T (pt) Composição para o tratamento de lesões da pele e/ou unhas
IL214133A0 (en) Skin treatment
IL215831A (en) A drug containing allopurinol for use in the treatment of hand-foot skin reaction
ZA201008693B (en) Foam skin care cream
GB0822486D0 (en) Compounds for use in the treatment of pain
SI2556834T1 (sl) Tetratiomolibdat za uporabo pri zdravljenju ishemične-reperfuzijske poškodbe srca
SMT202100576T1 (it) Dispositivi per il trattamento di lesioni cutanee
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
PL2424602T3 (pl) System do dostarczania środka leczniczego do skóry pacjenta
EP2404611A4 (en) Peptide for the prophylactic or therapeutic treatment of skin tumors, in the initial stages
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
GB0805784D0 (en) Hand or foot covers for use in skin treatment
ZA201005770B (en) The treatment of damaged skin
GB2473735B (en) Skin treatment formulation
GB0819037D0 (en) Skin treatment formulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees